CJC-1295 vs Ipamorelin vs Sermorelin 2026: Full Comparison
CJC-1295 with DAC and sermorelin belong to the GHRH-analog class; ipamorelin is a GH-secretagogue/ghrelin-receptor agonist. They stimulate endogenous GH through different receptor systems, rather than being growth hormone themselves. “CJC-1295 no DAC” or Mod GRF 1-29 must also be distinguished from the long-acting DAC molecule studied in the 2006 trials.
CJC-1295 DAC increased trough and mean GH while preserving GH pulsatility in the published human experiment. Long exposure is not synonymous with elimination of pulses. This comparison separates that direct observation from proposed combination effects.
Quick Comparison Table
| Material | Receptor class | Identifiable evidence | Important limit |
|---|---|---|---|
| CJC-1295 DAC | Long-acting GHRH analog | 2006 human PK/PD studies; estimated half-life 5.8–8.1 days | Increased trough/mean GH with preserved pulsatility |
| Mod GRF 1-29 / no-DAC label | Shorter GHRH-analog material | Verify the exact sequence and a matching study | Teichman 2006 did not establish a universal 30-minute no-DAC half-life |
| Ipamorelin | GHRP/ghrelin-receptor class | Raun 1998: rat pituitary, rat and swine GH-response experiments | Hormone selectivity in those models is not universal human safety |
| Sermorelin | GHRH(1–29)NH2 | Historical diagnostic/clinical GHRH-analog literature | A pharmaceutical history does not authorize a research vial |
For combination evidence, see the GH-axis review.
Mechanism - Three Pathways, Two Receptor Systems
The receptor-class distinction is useful, but conclusions about a particular combination require a study of that combination.
GHRH Analogs
CJC-1295 DAC is a long-acting GHRH analog designed to bind albumin. Sermorelin is GHRH(1–29)NH2. Materials sold without DAC require a separate identity and exposure assessment; they were not the long-acting material evaluated in Teichman 2006.
Ipamorelin and Hormone Selectivity
Raun 1998 demonstrated GH release in primary rat pituitary cells, rats and swine. In swine, ipamorelin did not increase ACTH/cortisol above the GHRH comparison in the tested conditions, unlike GHRP-2/6. This does not establish universal absence of off-target effects, including aldosterone, in every population.
Class Synergy Versus a Particular Stack
Bowers 1990 and 2004 tested specific GHRP/GHRH interventions and observed greater combined GH responses. The 2004 peptide was GHRP-2, not ipamorelin. These studies motivate a class-based hypothesis but do not directly validate a Mod GRF 1-29/ipamorelin regimen or prove that it is the most widely studied stack.
Pharmacokinetics & Pulsatility
Teichman et al. (2006) studied long-acting CJC-1295 in healthy adults and estimated a 5.8–8.1 day half-life, with prolonged GH/IGF-I changes. Ionescu and Frohman (2006) directly measured overnight GH pulses before and one week after CJC-1295. Pulse frequency and magnitude were preserved, while trough GH rose approximately 7.5-fold and mean GH rose 46% in that experiment.
A long circulating half-life and elevated baseline secretion can coexist with GH pulses. The cited studies did not directly compare all four catalogue materials; each sequence and formulation requires its own exposure assessment. Report exposure and GH secretion measurements separately.
Research Evidence Side-by-Side
The most defensible comparison is by measured experiment, not a ranking of recovery, sleep or neurological usefulness.
GH and IGF-I Measurements
The 2006 DAC studies measured human GH/IGF-I responses. Raun’s ipamorelin study measured animal/cell GH responses. These cannot establish a head-to-head ranking of IGF-I elevation across all compounds.
Body Composition
GH secretion is a biomarker, not a direct measurement of improved body composition. The sources here do not establish that a CJC-1295/ipamorelin combination produces the strongest rodent body-composition outcome.
Sleep and Recovery
Findings for GHRH generally require the exact tested compound and sleep endpoint before being assigned to Mod GRF or CJC-1295. The cited sources do not validate a recovery-oriented catalogue regimen.
Cognition
A result obtained with ghrelin itself is not automatically an ipamorelin result. The sources here do not establish an ipamorelin-specific cognitive advantage.
Stacking - When Researchers Use Combinations
The class-based combination hypothesis can be studied, but a specific CJC-1295/ipamorelin pair needs its own matched single-agent and combination data. The Bowers studies used other specified GHRH/GHRP interventions.
CJC-1295 DAC plus ipamorelin should not be dismissed as “mechanistically inconsistent” on the claim that DAC eliminates pulses: the published CJC-1295 experiment preserved them. Conversely, that correction does not establish that the pair is superior or clinically useful. Select the model, sampling schedule and endpoints needed to answer the actual question.
Safety, Regulatory Status, and Research Gaps
The short 2006 CJC-1295 studies provide limited clinical exposure information, not a comprehensive chronic safety dossier. Animal hormone selectivity with ipamorelin cannot establish safety of a human regimen or a separately supplied research vial.
As checked on 5 October 2026, the FDA safety-risk page discusses CJC-1295 and ipamorelin separately, including characterization/immunogenicity concerns. Product identity, applicable authorization and the exact formulation must be assessed independently of a mechanism review.
How to Choose for Your Research
For prolonged exposure and human GH-pulse questions, begin with the actual CJC-1295 DAC studies. For ipamorelin-specific signaling, begin with its defined cell/animal experiments. For class combinations, identify the original peptides used rather than substituting catalogue compounds by receptor class alone.
For procurement, match sequence, DAC modification, salt and lot data to the protocol. Do not select a compound using an unsupported daily schedule, a presumed loss of pulsatility, or unmeasured sleep/cognitive advantages.
Conclusion
The useful distinction is receptor class, molecular identity and measured exposure. CJC-1295 DAC can increase sustained GH/IGF-I measures while preserving GH pulses. GHRH/GHRP class synergy is a reason to investigate combinations, but does not validate a specific catalogue stack or its dosing schedule.
Source this peptide for your research
Order CJC-1295 (DAC)Research source
Source CJC-1295 (DAC) for your research
Compare available sizes and check the matching batch certificate before ordering.
View productFrequently Asked Questions
What's the difference between CJC-1295 with and without DAC?
DAC extends exposure through albumin binding. The published long-acting CJC-1295 trial estimated 5.8–8.1 days, and the subsequent pulse study preserved GH pulsatility while raising trough/mean GH. Mod GRF/no-DAC is a different supplied material; the cited DAC trial did not establish its universal 30-minute PK.
Are these the same as actual human growth hormone (HGH)?
No. HGH (somatropin) is the 191-amino-acid pituitary hormone itself. CJC-1295, Ipamorelin, and Sermorelin are all secretagogues - they trigger the pituitary to release endogenous GH, but they are not GH themselves. The response depends on the pituitary and the exact secretagogue, exposure and sampling method. The CJC-1295 DAC pulse study found preserved pulse frequency and magnitude alongside higher trough and mean GH; it did not establish that every secretagogue produces a more physiological pattern than exogenous GH.
Is Ipamorelin a GHRH analog?
No - Ipamorelin is frequently mislabeled as a GHRH analog in popular peptide commentary, but it is mechanistically a separate class. Ipamorelin is a selective ghrelin / GHSR-1a agonist, acting on the growth hormone secretagogue receptor - a different receptor system from the GHRH receptor that CJC-1295 and Sermorelin target. The two receptor classes converge on GH release but use different intracellular signaling (Gαs/cAMP for GHRHR, Gαq/IP₃/Ca²⁺ for GHSR-1a). This receptor distinction motivates a combination hypothesis. It does not itself validate a particular CJC-1295/ipamorelin stack; the cited Bowers experiments used other specified GHRH/GHRP interventions.
Sermorelin vs CJC-1295: which has more research?
Sermorelin has a historical clinical literature, while the directly cited CJC-1295 evidence includes the 2006 healthy-adult DAC studies. This page does not perform a bibliometric ranking. A larger historical literature does not make any research-grade formulation clinically authorized or interchangeable.
Is the CJC-1295 + Ipamorelin stack still relevant in research?
A class-based rationale exists, but the cited Bowers experiments used specified GHRH/GHRP interventions rather than establishing a particular Mod GRF/ipamorelin schedule. CJC-1295 DAC was shown to preserve pulses; prolonged exposure alone does not determine the response to a combination.
Where can I source research-grade material?
Review the lot-specific report for the exact sequence, modifications, HPLC method/trace and interpreted MS result. A compatible intact mass supports composition but is not complete sequence confirmation. If stock concentration matters, obtain a quantitative target-content basis; HPLC area purity is separate from net content. Select acceptance criteria for the model rather than assuming one percentage measures every quality attribute.
Scientific References
- Teichman et al. 2006. Long-acting CJC-1295 PK/PD. PMID: 16352683 - Primary source[PubMed Reference]
- Ionescu and Frohman 2006. Pulsatile secretion persists. PMID: 17018654 - Primary source[PubMed Reference]
- Raun et al. 1998. Ipamorelin animal/cell pharmacology. PMID: 9849822 - Primary source[PubMed Reference]
- Bowers et al. 1990. GHRP/GHRH combination experiment. PMID: 2108187 - Primary source[PubMed Reference]
- Bowers et al. 2004. GHRP-2/GHRH experiments. PMID: 15126555 - Primary source[PubMed Reference]
- FDA current CJC-1295/ipamorelin safety-risk page - Primary source
Related Research Peptides
CJC-1295 (DAC)
